

Table S1 The demographic data of PM/DM patients with ILD.

PM/DM-ILD (n = 116)		
Women <i>n</i> (%)		83 /116 (71.6%)
Age (year)		56.0 ± 14.8 ^a
Smoking <i>n</i> (%)		37 /106 (34.9%)
Follow-up period (months)		47.0 [21.0-75.5] ^b
Type (<i>n</i>)		PM 22, DM 51, CADM 43
Manifestation <i>n</i> (%)	Eruption	97 /115 (84.3%)
	Muscle weakness	76/115 (66.1%)
	Dysfunction of swallowing	22/114 (19.3%)
	fever	53/115 (46.1%)
Baseline data	CK (U/l)	360 [115-1,496] ^b
	LDH (U/l)	369 [279-526] ^b
	KL-6 (U/ml)	673 [453-1,030] ^b
	CRP (mg/dl)	0.57 [0.15-1.78] ^b
	Lymphocyte (/μl)	971 [696-1,386] ^b
	Albumin (g/dl)	3.42 ± 0.56 ^a
	PaCO ₂ (mmHg)	37.3 [34.3-40.3] ^b
	Ferritin (ng/ml)	360 [165-843] ^b
Autoantibody <i>n</i> (%)	IgG (mg/dl)	1,476 [1,295-1,813] ^b
	Anti-Jo-1 Ab	21/ 114 (18.4%)
	Anti-ARS Ab	9/ 45 (20.0%)
	Anti-MDA5 Ab	8/31 (25.8%)
	Anti-TIF-1γ Ab	2/2 (100%)
	ANA (>80×)	33/111 (29.7%)
	Anti-SS-A Ab	15/80 (18.8%)
Malignancy (<3 years) <i>n</i> (%)		21/112 (18.8%)
	Initial PSL dose (mg/kg/day)	0.83 ± 0.29 ^a
Treatment	mPSL pulse <i>n</i> (%)	77 /116 (66.4%)
	IVCY <i>n</i> (%)	48 /116 (41.4%)
	Calcineurin inhibitor <i>n</i> (%)	81/115 (70.4%)
	Combination therapy ^c <i>n</i> (%)	40 /116 (34.5%)
	IVIg <i>n</i> (%)	13/115 (11.3%)
	Death <i>n</i> (%)	28 /116 (24.1%)
Prognosis	ICU management <i>n</i> (%)	13 /116 (11.2%)
	Serious infection <i>n</i> (%)	38 /116 (32.8%)

^aThe data are shown as the mean ± standard deviation.^bValues are the median [interquartile range].^cCombination therapy includes glucocorticoid, IVCY and calcineurin inhibitors.